Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | FNTA | P49354 | 1/20 | 0.35 |
| ▸ | FNTB | P49356 | 1/20 | 0.35 |
| ▸ | SPR | P35270 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16592794 | 0.87 | NOTUM (0.46) | HSP90AB1HSP90AA1CCR2KCNH2FNTA | |
| SCHEMBL21465759 | 0.86 | HSP90AB1 (0.40) | HSP90AB1HSP90AA1HPGDPTGS1 | |
| SCHEMBL12004429 | 0.82 | PTGS1 (0.40) | HSP90AB1HSP90AA1CCR2KCNH2PTGS1 | |
| SCHEMBL723952 | 0.82 | ABHD6 (0.49) | HSP90AA1CCR2KCNH2HPGDPTGS1 | |
| SCHEMBL7878257 | 0.80 | FNTA (0.46) | HSP90AB1HSP90AA1CCR2KCNH2HPGD | |
| SCHEMBL29883147 | 0.80 | ESR2 (0.55) | CCR2KCNH2MEN1KMT2AFNTA | |
| SCHEMBL2679894 | 0.80 | ESR2 (0.55) | CCR2KCNH2MEN1KMT2AFNTA | |
| SCHEMBL28005866 | 0.78 | CCR2 (0.51) | CCR2KCNH2 | |
| SCHEMBL14863290 | 0.77 | CCR2 (0.42) | CCR2HPGDMEN1KMT2AFNTA | |
| SCHEMBL29249322 | 0.77 | PTGS1 (0.46) | HSP90AB1HSP90AA1HPGDPTGS1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113880866-B | Aza-tetrahydronaphthyridine compound, preparation method thereof, pharmaceutical composition and application thereof | 上海维申医药有限公司 | 2022-09-27 | — | — | CN | disclosed |
| CN-113880866-A | Aza-tetrahydronaphthyridine compound, preparation method thereof, pharmaceutical composition and application thereof | 上海维申医药有限公司 | 2022-01-04 | — | — | CN | disclosed |
| CN-103119035-B | Heterogeneous ring compound and they are as the purposes of GSK-3 inhibitor | ABBOTT GMBH & CO.KG (DE) | 2015-09-30 | — | — | CN | disclosed |
| US-20120115900-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2012-05-10 | — | — | US | disclosed |
| EP-2421863-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AND THEIR MEDICAL USE | NeuroSearch AS (DK) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010122064-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115900-A1 | SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AND THEIR MEDICAL USE | KCNQ1, KCNQ2, KCNQ5 | HSP90AB1 2393/4885HSP90AA1 2922/4885CCR2 4807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.